中性粒细胞减少性发热

参考文献

关键文献

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb 15;52(4):e56-93.全文  摘要

Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct;36(30):3043-54.全文  摘要

Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000 Aug;18(16):3038-51. 摘要

Aapro MS, Bohlius J, Cameron DA, et al; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 Jan;47(1):8-32. 摘要

参考文献

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb 15;52(4):e56-93.全文  摘要

2. Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 2009 Mar;144(5):677-85.全文  摘要

3. Tai E, Guy GP, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017 Jun;13(6):e552-61.全文  摘要

4. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005 May 1;103(9):1916-24.全文  摘要

5. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct;36(30):3043-54.全文  摘要

6. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003 Dec;44(12):2069-76. 摘要

7. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005 Jun-Jul;10(6):427-37.全文  摘要

8. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988 Dec;148(12):2561-8. 摘要

9. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000 Aug;18(16):3038-51. 摘要

10. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003 May 1;36(9):1103-10.全文  摘要

11. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008 Feb;6(2):109-18. 摘要

12. Aslani A, Smith RC, Allen BJ, et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer. 2000 Feb 15;88(4):796-803.全文  摘要

13. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003 Dec 15;21(24):4524-31. 摘要

14. Kloess M, Wunderlich A, Trumper L, et al. Predicting hematotoxicity in multicycle chemotherapy. Blood. 1999;94(10 Suppl 1):87A (abstract 381).

15. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004 Nov 1;22(21):4302-11.全文  摘要

16. Morrison VA, Caggiano V, Fridman M, et al. A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients (abstract). J Clin Oncol. 2004 Jul 22(14 Suppl):8068.全文

17. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive Non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Apr;37(3-4):351-60. 摘要

18. Silber JH, Fridman M, DiPaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol. 1998 Jul;16(7):2392-400. 摘要

19. Family L, Li Y, Chen LH, et al. A study of novel febrile neutropenia risk factors related to bone marrow or immune suppression, barrier function, and bacterial flora. J Natl Compr Canc Netw. 2018 Oct;16(10):1201-8.全文  摘要

20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic growth factors [internet publication].全文

21. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199-212.全文  摘要

22. Aapro MS, Bohlius J, Cameron DA, et al; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 Jan;47(1):8-32. 摘要

23. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005 Feb 20;23(6):1178-84.全文  摘要

24. Kuderer NMD. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007 Jul 20;25(21):3158-67. 摘要

25. Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011 Sep 23;11:404.全文  摘要

26. Bond TC, Szabo E, Gabriel S, et al. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract. 2018 Sep;24(6):412-23.全文  摘要

27. Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015 Feb;23(2):525-45. 摘要

28. Skoetz N, Bohlius J, Engert A, et al. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. Cochrane Database Syst Rev. 2015 Dec 21;(12):CD007107.全文  摘要

29. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971 May 13;284(19):1061-5. 摘要

30. Strojnik K, Mahkovic-Hergouth K, Novakovic BJ, et al. Outcome of severe infections in afebrile neutropenic cancer patients. Radiol Oncol. 2016 Feb 10;50(4):442-8.全文  摘要

31. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.全文  摘要

32. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975 May;135(5):715-9. 摘要

33. Press OV, Ramsey PG, Larson EB, et al. Hickman catheter infections in patients with malignancies. Medicine (Baltimore). 1984 Jul;63(4):189-200. 摘要

34. Maschmeyer G, Carratalà J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2015 Jan;26(1):21-33.全文  摘要

35. Valdivieso M, Gil-Extremera B, Zornoza J, et al. Gram-negative bacillary pneumonia in the compromised host. Medicine (Baltimore). 1977 May;56(3):241-54. 摘要

36. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992 Feb;10(2):316-22. 摘要

37. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004 Aug;12(8):555-60. 摘要

38. Escalante CP, Weiser MA, Manzullo E, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer. 2004 Sep;12(9):657-62. 摘要

39. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 Feb 10;33(5):465-71. 摘要

40. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985 Sep;145(9):1621-9. 摘要

41. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016 Sep;27(suppl 5):v111-8.全文  摘要

42. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy. J Clin Oncol. 2018 Feb 20;36(14):1443-53.全文  摘要

43. Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol. 2011 Nov;22(11):2358-65.全文  摘要

44. Carstensen M, Sørensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol. 2008 May-Jun;6(5):199-208. 摘要

45. Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013 Jun 29;(6):CD003038.全文  摘要

46. Harter C, Schulze B, Goldschmidt H, et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 2006 Feb;37(4):373-9. 摘要

47. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 2006 Aug 15;43(4):447-59. 摘要

48. Bucaneve G, Micozzi A, Picardi M, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol. 2014 May 10;32(14):1463-71. 摘要

49. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections [internet publication].全文

50. Ram R, Halavy Y, Amit O, et al. Extended vs bolus infusion of broad-spectrum β-lactams for febrile neutropenia: an unblinded, randomized trial. Clin Infect Dis. 2018 Sep 28;67(8):1153-60. 摘要

51. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992 Jun;14(6):1201-7. 摘要

52. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis. 1991 May;163(5):951-8. [Erratum in: J Infect Dis 1991 Oct;164(4):832.] 摘要

53. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006 Mar 1;42(5):597-607. 摘要

54. Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy - EORTC infectious diseases group trial XV. J Clin Oncol. 2013 Mar 20;31(9):1149-56.全文  摘要

55. Rolston KV, Frisbee-Hume SE, Patel S, et al. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer. 2010 Jan;18(1):89-94. 摘要

56. Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol. 2000 Nov 1;18(21):3699-706. 摘要

57. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007 May;7(5):338-48. 摘要

58. Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014 Oct 30;(10):CD003039.全文  摘要

59. Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD005197.全文  摘要

60. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 May 15;106(10):2258-66.全文  摘要

61. Lyman GH, Kuderer NM. Filgastrim in patients with neutropenia: potential effects on quality of life. Drugs. 2002;62 Suppl 1:65-78. 摘要

62. Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998 Nov;34(12):1857-64. 摘要

63. González-Barca E, Fernández-Sevilla A, Carratalà J, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999 Aug;18(8):539-44. 摘要

64. Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect. 2001 Feb;42(2):120-5. 摘要

65. Darmon M, Azoulay E, Alberti C, et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 2002 Dec;28(12):1775-80. 摘要

66. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997 Aug;25(2):247-59. 摘要

67. Carratalà J, Rosón B, Fernández-Sevilla A, et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 1998 Apr 27;158(8):868-72.全文  摘要

68. Lyman GH, Kuderer NM. Cost-effectiveness of myeloid growth factors in cancer chemotherapy. Curr Hematol Rep. 2003 Nov;2(6):471-9. 摘要

内容使用需遵循免责声明